Corvus Pharmaceuticals earnings were -$62.3M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest CRVS earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$12.1M, down 69.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CRVS reported annual earnings of -$62.3M, with 130.5% growth. The next CRVS earnings date is Jun 13, 2025.
Corvus Pharmaceuticals Earnings Reports & History FAQ
What were Corvus Pharmaceuticals's earnings last quarter?
On CRVS's earnings call on Invalid Date, Corvus Pharmaceuticals (NASDAQ: CRVS) reported Q4 2024 earnings per share (EPS) of -$0.16, up 23.08% year over year. Total CRVS earnings for the quarter were -$12.11 million. In the same quarter last year, Corvus Pharmaceuticals's earnings per share (EPS) was -$0.13.
The next CRVS earnings date is Invalid Date. Add CRVS to your watchlist to be reminded of Corvus Pharmaceuticals's next earnings date.
Is Corvus Pharmaceuticals profitable or losing money?
As of the last Corvus Pharmaceuticals earnings report, Corvus Pharmaceuticals is currently losing money. Corvus Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$62.29 million, a 130.47% increase year over year.
What was CRVS's earnings growth in the past year?
As of Corvus Pharmaceuticals's earnings date in Invalid Date, Corvus Pharmaceuticals's earnings has grown year over year. CRVS earnings in the past year totalled -$62.29 million.
What are Corvus Pharmaceuticals's earnings expectations?
The current EPS estimate for Corvus Pharmaceuticals's earnings report in Invalid Date is -$0.12.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.